Monte Rosa Therapeutics Receivables

Monte Rosa Therapeutics (GLUE) currently reports a receivables of $9.8M as of June 2026. That compares with $2.4M in the prior-year period — up 315.2% year over year. Use the charts on this page to explore Monte Rosa Therapeutics's receivables history and peer comparisons.

Monte Rosa Therapeutics's receivables increased from $2.4M to $9.8M — a 315.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monte Rosa Therapeutics reported $9.8M in receivables as of June 2026. That compares with $2.4M in the prior-year period — up 315.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $9.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Monte Rosa Therapeutics, and consider following GLUE for alerts when major investors trade the stock.

Monte Rosa Therapeutics is classified in the Healthcare sector. On receivables, it currently shows $9.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing GLUE with unrelated industries.